FDA authorises Regeneron’s COVID-19 antibody treatment for injection

Organisation: Position: Deadline Date: Location:

The US Food and Drug Administration has approved a lower dose of Regeneron’s coronavirus treatment for injection, reports Axios.

The update to the company's emergency use authorisation, which was first issued in November, will make it easier for doctors to administer the treatment to coronavirus patients, since they can now do so by simple injection rather than intravenous infusion. Some health officials have said Regeneron’s monoclonal antibodies drug has been underused partly because not all clinics and hospitals are equipped to administer intravenous infusions, according to the Wall Street Journal.


Full Axios report (Open access)


See also from the MedicalBrief archives:


Regeneron antibody cocktail cuts COVID-19 hospitalisation and deaths


Injected antibody cocktail cuts COVID-19 infection risk by over 80%

Receive Medical Brief's free weekly e-newsletter

Related Posts

Thank you for subscribing to MedicalBrief

MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.

Thank you for taking the time to complete the form.